Ag-Biotech Startup Resurrect Bio Raises $8.1M
Resurrect Bio, a UK-based agricultural biotechnology startup, has raised $8.1 million in a Series A funding round. The company is developing disease-resistant crops using advanced genome editing techniques, representing growth in applied life sciences beyond human medicine.
- The investment round was led by Corteva Catalyst, the venture capital arm of global agricultural science company Corteva, with participation from investors like Calculus Capital, Pymwymic, and AgFunder. - Resurrect Bio was spun out of The Sainsbury Laboratory, a world-renowned plant science research institute in the UK, and was co-founded by CEO Dr. Cian Duggan, Prof. Tolga Bozkurt, and Prof. Sophien Kamoun. - The company's core technology is a platform named FloraFold®, which uses AI and computational biology to identify and "resurrect" a crop's own suppressed disease resistance genes through precise gene editing. - This approach aims to provide a sustainable alternative to chemical pesticides by restoring a plant's natural ability to fight off threats like fungal diseases, oomycetes, and nematodes. - The company's work exemplifies a key career path in ag-biotech, where bioinformatics scientists and genetic engineers analyze genetic data and modify plant genes, a contrast to patient-facing medical roles. - CEO Dr. Cian Duggan’s career path from a PhD in Plant Molecular Biology to a "scientist-founder" highlights a trajectory in life sciences that combines deep scientific research with entrepreneurship and business development.
